N-Gene Inc.
http://ngene.us/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From N-Gene Inc.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Q1 2024 Posts Big M&A Total Led By Novo Holdings’ Catalent Takeout
The $16.5bn deal, intended to increase Novo Nordisk’s production of semaglutide-containing products, led a $36bn-plus quarter for M&A transactions, according to Evaluate.
Andera Reflects On Revitalized Biotech Scene
After AstraZeneca’s acquisition of Amolyt made the Paris-based investment group a tidy profit, Andera spoke to Scrip about the rejuvenated investment market in Europe.
AstraZeneca Spends $800m On Amolyt And Awaits A Readout
The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- N-Gene Research Laboratories, Inc.
- N-Gene Research and Development, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice